A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04586426)
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Colorado Blood Cancer Institute — Denver, Colorado
- Emory University — Atlanta, Georgia
- Mayo Clinic — Rochester, Minnesota
- Washington University St. Louis School Medicine Siteman Cancer Center — St Louis, Missouri
- Mount Sinai Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Atrium Health — Charlotte, North Carolina
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health And Science University — Portland, Oregon
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- St Vincents Hospital Melbourne — Fitzroy,
- Royal Perth Hospital — Perth,
- Arthur J E Child Comprehensive Cancer Centre — Calgary, Alberta
- Alberta Health Services — Edmonton, Alberta
- Princess Margaret Cancer Centre University Health Network — Toronto, Ontario
- McGill University Health Centre — Montreal, Quebec
- Hadassah Medical Center — Jerusalem,
- Sheba Medical Center — Ramat Gan,
- Tel Aviv Sourasky Medical Center — Tel Aviv,
- Kanazawa University Hospital — Kanazawa,
- Nagoya City University Hospital — Nagoya,
- Osaka University Hospital — Osaka,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.